Primary Pulmonary Hypertension
Vasodilator (Prostacyclin-Flolan) Medical
Centers in the landmark Primary Pulmonary Hypertension (PPH)
Study
Vasodilator protocols are only performed in
certain limited medical centers throughout the country. The thirteen centers
listed below were originally involved in the landmark study of the
vasodilator, prostacyclin (Flolan):
FLOLAN MEDICAL CENTERS INITIAL TRIAL
(1) Columbia University in New York, New
York;
(2) University of Maryland in Baltimore,
Maryland;
(3) The University of Alabama in Birmingham,
Alabama;
(4) Harbor-UCLA Medical Center in Torrance,
California;
(5) Cedars Sinai Medical Center in Los
Angeles, California;
(6) University of North Carolina, Chapel
Hill, North Carolina;
(7) Mayo Clinic Medical Center in Rochester,
Minnesota;
(8) The University of Illinois in Chicago,
Illinois;
(9) The University of Colorado Health
Sciences Center in Denver, Colorado;
(10) The Duke Medical Center in Durham, North
Carolina;
(11) Baylor College of Medicine in Houston, Texas;
(12) The Presbyterian-University Hospital in
Pittsburgh, Pennsylvania; and
(13) McGill University in Montreal, Canada.
FLOLAN TREATMENT
The most exciting advance in the treatment of PPH has been the introduction
of intravenous prostacyclin or Flolan. Flolan became clinically available for
PPH in 1996, but has been used experimentally for over seven years. Flolan can
markedly reduce symptoms, reduce pulmonary artery pressures, and most
importantly improve the prognosis of many patients with severe forms of PPH.
Prostacyclin is a naturally occurring relaxing factor released by the lining
cells of normal arteries. Patients with PPH do not produce sufficient
prostacyclin and have excessive naturally occurring constrictors such as
endothelin. The initial benefit of Flolan may be seen within days, but the
maximal effect is delayed to as long as three months.
PPH patients on Flolan or calcium channel blockers must be followed on a
regular basis in an experienced center to determine the effect of treatment
and decide when and if lung or heart lung transplant should be considered.
Patients on Flolan are usually listed for transplant, but are placed in a
holding pattern if their symptoms are improved and prognosis appears good.
PPH
LAWSUITS - LEGAL & FINANCIAL HELP FOR PPH VICTIMS
 If
you or a loved one have been diagnosed with Primary Pulmonary Hypertension (PPH),
then you may have a right to file a individual legal action against the
manufacturers of the diet pills or other products that caused your PPH. Due to
the nature of this serious and devastating disease process, PPH patients are
urged to contact an attorney immediately after he or she has been informed of
their Primary Pulmonary Hypertension diagnosis. Many important legal issues
need to be addressed early after a PPH diagnosis, that can affect the
outcome of the PPH litigation. Call us for a Free Confidential Consultation.
Talk with a Board Certified Personal Injury Trial Lawyer about your legal
rights of a PPH claim against the diet drug industry and others. No Fees or
Expenses Charged unless we make a Recovery for You.
Call
Us Toll Free at 1-800-883-9858 or 1-800-468-4878 or E-mail
us your questions on Free
Case Evaluation Form
|
Legal Assistance
for PPH & Diet Drug Victims since 1997
